Pre-surgery protein supplement for colorectal cancer patients with low muscle mass
Tests a protein supplement before surgery in colorectal cancer patients with sarcopenia.
Plain-language title generated from the registry record
Registry title: Sarcopenia in Colorectal Cancer Patients, Intervention Study
Key facts
- Where
- L'Hospitalet de Llobregat, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 70 or older who have colon cancer and are about to have planned surgery. It compares those with and without sarcopenia (muscle loss).
- Age
- 70 years or older
- Sex
- All sexes can join
- Disease stage
- Colon adenocarcinoma without metastases found at the same time as the cancer; surgery is not urgent
Main reasons for not taking part
- Rectal cancer
- Another cancer in the last 5 years
- Clinically significant heart disease (congestive heart failure, symptomatic coronary disease)
- Pregnancy or breastfeeding
- A medical or mental condition that prevents giving informed consent
Read by machine on 12 November 2026.
Where in Spain
- Hospital Universitari de BellvitgeL'Hospitalet de Llobregat, SpainContact: Ricardo Frago, Ph DTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hospital Universitari de Bellvitge
- Trial code
- NCT05491434
- Record updated
- 20 May 2025
- Original description
The sarcopenia is a new concept for evaluating the functional status of patients, introduced during the last 20 years. This is defined as the relationship between the deterioration of muscle mass and the decrease in strength, the metabolic rate, the aerobic capacity and subsequently the evaluation of the functional status. The sarcopenia has been estimated to affect 5% to 13% of people aged between 60 and 70 years, increasing from 11% to 50% in those aged 80 years and older. In a study by Lieffers et al. of a total of 234 patients with colorectal cancer, with a mean age of 63 years according to the values observed by Prado et al., the prevalence of sarcopenia would be around 39%, being able to reach up to 60% in patients with chronic diseases.Read full original descriptionShow less
Intervention, Non-randomized Controlled, Non-masked and Comparative Study of Presurgical Conditioning in Colorectal Cancer Patients Who Present With Sarcopenia
The sarcopenia is a new concept for evaluating the functional status of patients, introduced during the last 20 years. This is defined as the relationship between the deterioration of muscle mass and the decrease in strength, the metabolic rate, the aerobic capacity and subsequently the evaluation of the functional status. The sarcopenia has been estimated to affect 5% to 13% of people aged between 60 and 70 years, increasing from 11% to 50% in those aged 80 years and older. In a study by Lieffers et al. of a total of 234 patients with colorectal cancer, with a mean age of 63 years according to the values observed by Prado et al., the prevalence of sarcopenia would be around 39%, being able to reach up to 60% in patients with chronic diseases.
The goal of this study is to compare the cumulative incidence of post-surgical complications due to infection at 30 days between the group of patients without sarcopenia and the group of patients with sarcopenia with an intervention based on a nutritional supplement + physical exercise.
Inclusion: Age ≥ 70 years old,; Colon adenocarcinoma without synchronous metàstasis,; No urgent surgery,; ECOG performance status ≤ 2,; no pregnancy or lactation,; signature of the informed consent,; ability to comply with the study indications.
Exclusion: Concomitant neoplastic disease in the last 5 years; Concomitant uncontrolled or stable medical condition,; medical or mental condition of the patient that compromises the authorization of informed consent,; Clinically significant heart disease (congestive heart failure, symptomatic coronary disease); rectal càncer,; Refusal to participate in the study.